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Since the former evidence of biologic actions of neurosteroids in the central nervous
system, also the peripheral nervous system (PNS) was reported as a structure affected
by these substances. Indeed, neurosteroids are synthesized and active in the PNS,
exerting many important actions on the different cell types of this system. PNS is a
target for neurosteroids, in their native form or as metabolites. In particular, old and
recent evidence indicates that the progesterone metabolite allopregnanolone possesses
important functions in the PNS, thus contributing to its physiologic processes. In this
review, we will survey the more recent findings on the genomic and non-genomic
actions of neurosteroids in nerves, ganglia, and cells forming the PNS, focusing on the
mechanisms regulating the peripheral neuron-glial crosstalk. Then, we will refer to the
physiopathological significance of the neurosteroid signaling disturbances in the PNS, in
to identify new molecular targets for promising pharmacotherapeutic approaches.
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INTRODUCTION
The importance of endogenous neurosteroids for the control of the peripheral nervous
system (PNS) become increasingly relevant in the last decades. Since the 1980 last
century, when Baulieu and colleagues (Baulieu, 1997) introduced the term “neurosteroids”
to indicate steroids that were synthesized de novo in the brain, also the PNS has
Abbreviations: 3α-diol, 5α-androstane-3α,17β-diol; 3β-diol, 5α-androstane-3β,17β-diol; 3α-HSD, 3α-hydroxysteroid
dehydrogenase; 3β-HSD, 3β-hydroxysteroid dehydrogenase; 5α-R, 5α-reductase; 5HT3, 5-hydroxytryptamine type 3; ALLO,
allopregnanolone; AR, androgen receptor; CREB, cAMP response element-binding protein; DHEA, dehydroepiandrosterone;
DHP, dihydroprogesterone; DHT, dihydrotestosterone; DRG, dorsal root ganglia; E2, 17β-estradiol; EAAC1, excitatory
amino acid transporter 1; EGR1/Krox-24 early growth response (EGR1/Krox-24); EGR2/Krox-20 early growth response
2 (EGR2/Krox-20); Egr3, early growth response 3; ER, estrogen receptor; ERK1/2, extracellular signal-regulated protein
kinase 1 and 2; FAK, focal adhesion kinase; GABA, γ-aminobutirric acid; GABA-A, GABA type A receptor; GABA-
B, GABA type B receptor; GAD67, glutamic acid decarboxylase of 67 kDa; GFAP, glial fibrillary acidic protein; GPCR,
G protein-coupled receptor; GPR30, GPCR ER-1 or GPER1; GR, glucocorticoid receptor; LXR, liver X receptor; MAG,
myelin associated glycoprotein; mAR, membrane androgen receptor; MEP, motor exit point; mER, membrane estrogen
receptor; mGR, membrane glucocorticoids receptor; mPR, membrane progesterone receptor; MR, mineralocorticoid
receptor; NCV, nerve conduction velocity; NMDA, N-Methyl-D-aspartate; Olig1, oligodendrocyte transcription factor 1; P0,
glycoprotein P0; P450C17, 17α-hydroxylase/17,20-lyase; P450scc, P450 side-chain cleavage enzyme; p75-NTR, neurotrophin
receptor p75; PAQR, progestin and adipoQ receptor family; PGRMC-1, PR membrane component-1; PHTPP, 2-Phenyl-
3-(4-hydroxyphenyl)-5,7-bis(trifluoromethyl)-pyrazolo[1,5-a]pyrimidine; PK-A, protein kinase A; PK-C, protein kinase C;
PMP22, peripheral myelin protein 22; PNS, peripheral nervous system; PR, progesterone receptor, PREG, pregnenolone;
PROG, progesterone; SC, Schwann cells; Shh, sonic hedgehog; Src, tyrosine protein kinase Src; SRC1, steroid nuclear receptor
coactivator; Sox-10, SRY-box10; StAR, steroidogenic acute regulatory protein; STZ, streptozotocin; T, testosterone; THDOC,
tetrahydrodesoxycorticosterone; THP, tetrahydroprogesterone; TSPO, translocator protein.
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been referred as an important target of their action. In the
PNS, the neuroactive steroids (comprising the aforementioned
neurosteroids as well as the hormonal steroids) are synthesized
and/or metabolized in active forms and exert important
physiopathologic functions.
The neurosteroidogenic machinery includes a set of enzymes
(Figure 1), starting from P450 side-chain cleavage (P450scc),
which convert cholesterol into pregnenolone (PREG) in
mitochondria, moving to the 3β-hydroxysteroid-dehydrogenase
(3β-HSD), that converts PREG into progesterone (PROG) or the
17α-hydroxylase/17,20-lyase (P450C17), converting PREG into
dehydroepiandrosterone (DHEA). These steroids may be then
metabolized into androgens, androstenediol, androstenedione
and testosterone (T). Furthermore, by the action of the
enzyme P450 aromatase the androgens androstenedione and
T are converted into the estrogens estrone and 17β-estradiol
(E2), respectively.
Most of these enzymes, as well as their metabolic products
PROG, PREG, T, DHEA, and E2, have been found in PNS
(Caruso et al., 2008). In particular, the glial Schwann cells
(SC) of the PNS possess the enzymatic machinery required
to produce the neurosteroids: P450scc, 3β-HSD, etc., (Celotti
et al., 1992; Melcangi et al., 2001; Schumacher et al., 2001).
The activity of some steroidogenic enzymes in SC is neuronal
dependent, such as the 3β-HSD, that raised in the presence
of neurons (Chan et al., 2000; Robert et al., 2001). Dorsal
root ganglia (DRG) express the P450scc and 3β-HSD but not
other steroidogenic enzymes, indicating that other autocrine
or paracrine mechanisms might influence the steroidogenesis
in the soma of primary sensory neurons (Schaeffer et al.,
2010). Additionally, the enzymatic complexes formed by the
5α-reductase (5α-R) and the 3α-hydroxysteroid-dehydrogenase
(3α-HSD) was found in the PNS (Figure 1), primarily in
SC (Melcangi et al., 1990; Celotti et al., 1992; Melcangi
et al., 1992, 1999b). This enzymatic complex converts steroids
possessing the delta(4)-3-keto configuration into their more
active 5α-3α-reduced metabolites, the so-called neuroactive
steroids (Celotti et al., 1992). Thereby, the PROG is converted
into dihydroprogesterone (DHP) and then into 5α-pregnan-
3α-ol-20-one, also named tetrahydroprogesterone (THP) or
allopregnanolone (ALLO); similarly, the steroid T is converted
into dihydrotestosterone (DHT) then into 5α-androstane-
3α,17β-diol (3α-diol). The 5α-reduced intermediate metabolite
DHP and DHT can be further converted, by the enzyme 3β-HSD,
into 5α-pregnan-3β-ol-20-one (also named isopregnanolone) or
5α-androstane-3β,17β-diol (3β-diol), respectively (Giatti et al.,
2015; Figure 1).
The PNS showed also the presence of other important factors
supporting de novo local synthesis of neuroactive steroids. For
instance, those factors regulating the translocation of cholesterol
into the mitochondria, likely the steroidogenic acute regulatory
protein (StAR) and the translocator protein of 18 kDa (TSPO),
as well as the liver X receptor (LXR), were found to be present
and active in peripheral nerves. TSPO was formerly considered as
a crucial protein for steroid biosynthesis (Li and Papadopoulos,
1998). More recent and debated observations, however, argued
the significance of TSPO in steroidogenesis and evidenced
its involvement in pathological conditions, like inflammation,
apoptosis and neurological diseases (e.g., Alzheimer’s disease
or multiple sclerosis); indeed, TSPO seems to be expressed
only in response to insults and pathological states (Bonsack
and Sukumari-Ramesh, 2018). In the PNS, the activation of
TSPO with the specific ligand Ro5-4864 improved the levels of
neuroactive steroids and exerted neuroprotective effects in the
peripheral nerves of streptozotocin (STZ)-induced diabetic rats
(Giatti et al., 2009). LXR is a ligand activated transcription factor
belonging to the nuclear receptor superfamily. It is important
for cholesterol biosynthesis, serving as a sensor that prevents
the excessive intracellular accumulation of cholesterol (Jakobsson
et al., 2012). In the PNS, its activation by specific ligands induces
neuroactive steroid synthesis in the sciatic nerve of STZ-induced
diabetic rats, thus ameliorating diabetes-induced neuropathy
(Cermenati et al., 2010).
Interestingly, the synthesis and the levels of neuroactive
steroids proved sexually dimorphic, in physiologic states
(Melcangi et al., 2016), as well as in peripheral neurodegenerative
conditions, such as the diabetic neuropathy (Pesaresi et al.,
2010). For instance, in the sciatic nerve of STZ-rats the
levels of PREG, T, DHT, and 3α-diol decreased in males,
whereas the levels of PROG, THP and isopregnanolone
drop down only in female (Pesaresi et al., 2010). In the
same rat model of diabetic neuropathy, the gonadectomy
ameliorates the nerve alterations in females but not in males
(Pesaresi et al., 2011a).
In this review, we will survey the recent findings of the
classical and non-classical, genomic and non-genomic action
of neuroactive steroids in peripheral nerves, ganglia and cells
forming the PNS, thereby focusing on the mechanisms regulating
the peripheral neuron-glial crosstalk.
MECHANISMS OF ACTION OF
NEUROACTIVE STEROIDS
In the PNS, the neuroactive steroids exert several biologic
functions, modulating the mitogenic activity, cell proliferation,
myelination process, nerve repair, and axonal conduction.
The neuroactive steroid actions occur through either
“classical” or “non-classical” receptors, which localized
both in the neuronal and in the glial compartment (i.e.,
SC) of the PNS. The classical action is generally genomic
and consists of the binding to intracellular receptors in the
target cells, followed by the regulation of gene transcription
(Slater et al., 1994). Conversely, the non-classic action is
more rapid and involves the modulation of membrane
receptors, such as neurotransmitter and neurotrophin
receptors, ion channels or the newest membrane steroid
receptors (Brann et al., 1995; Barabas et al., 2018). Commonly,
among the neurotransmitter receptors affected by neuroactive
steroids, there are the γ-aminobutyric acid (GABA) and
the N-Methyl-D-aspartate (NMDA) receptors (Lambert
et al., 1996; Rupprecht et al., 2001; Monnet and Maurice,
2006; Sedlacek et al., 2008). Moreover, the family of
steroid membrane receptors includes specific receptors for
estrogens, androgens, glucocorticoids and progestogens
(Levin, 2011). Whether these receptors are the classical
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FIGURE 1 | Scheme of principal neuroactive steroid biosynthetic and metabolic pathways, and their receptor interactions in the PNS. The main steroidogenic
enzymes, metabolites, and receptors modulating neuroactive steroid action are present in the cells of the PNS (i.e., Schwann cells and DRG neurons). These
steroidogenic pathways, through the intermediate pregnenolone (PREG), dehydroepiandrosterone (DHEA) and androstenediol lead to the synthesis of progestogens
(PROG, progesterone; DHP, dehydroprogesterone; THP, tetrahydroprogesterone also called ALLO, allopregnanolone; isopregnanolone), androgens (T, testosterone;
DHT, dihydrotestosterone; 3α-diol, 5α-androstane-3α,17β-diol; 3β-diol, 5α-androstane-3α,17β-diol) and estrogens (E2, 17β-estradiol). P450 side-chain cleavage
enzyme (P450scc); 17α-hydroxylase/17,20-lyase (P450C17); 17β-hydroxysteroid-dehydrogenase (17β-HSD); 5α-R, 5α-reductase;
3α-hydroxysteroid-dehydrogenase (3α-HSD); 3β-hydroxysteroid-dehydrogenase (3β-HSD); P450 aromatase (P450aro). These neuroactive steroids may act through
classical receptor (PR, progesterone receptor; AR, androgen receptor; ER estrogen receptor) or non-classical receptor (GABA type A receptor; NMDA receptor), see
text for details.
nuclear receptor, which localizes on the cell membrane, or
distinct receptors characterized by different proteins is still a
matter of debate.
Interestingly, the capability of neuroactive steroids to interact
with classical rather than non-classical receptors is ancillary
to their conversion into active compounds. For instance
(Figure 1), the progestogens PROG and DHP mainly exert
classical activity through the genomic PROG receptor (PR),
while their metabolite ALLO fulfills a non-classical activity
via the GABA type A (GABA-A) receptor. Indeed, ALLO is
one of the most re-known and important GABA-A receptor
modulators (Lambert et al., 2009; Faroni and Magnaghi, 2011),
while the progestogen metabolite isopregnanolone has proved
to antagonize the effect of ALLO at GABA-A receptor (Wang
et al., 2002). Similarly, androgen metabolites exert classical
and non-classical actions. For instance, (Figure 1) 3α-diol
activates the GABA-A receptor, whereas 3β-diol is an agonist
of the estrogen receptor (ER) beta (ERβ) (Lambert et al., 2003;
Handa et al., 2008).
Evidence on the involvement of all these receptors in
the different physiopathologic states affecting the PNS has
been fully reported.
GENOMIC ACTIONS OF NEUROACTIVE
STEROIDS IN PNS
Classical intracellular steroid receptors, such as PR, ER,
androgen receptor (AR), glucocorticoid receptor (GR), and
mineralocorticoid receptor (MR) were found in peripheral nerves
(Magnaghi et al., 1999, 2001; Jordan et al., 2002; Shaqura et al.,
2016) as well as in SC (Neuberger et al., 1994; Jung-Testas et al.,
1996; Groyer et al., 2006; Faroni and Magnaghi, 2011; Shaqura
et al., 2016) and DRG (Luo et al., 2008; Dong et al., 2012; Shaqura
et al., 2016; Figure 1). Generally, these classic receptors bind,
respectively, the progestogens PROG and DHP, the estrogens
E2 and estrone, the androgens DHEA, T and DHT, the
gluco/mineralocorticoids corticosterone, dehydrocorticosterone,
and deoxycorticosterone (Slater et al., 1994; Prough et al., 2016).
In the PNS, E2 promoted the proliferation and differentiation
of SC, in vitro and in vivo, thus fostering the myelination
process (Chen et al., 2016; Gu et al., 2018). By the way, some
of these effects were inhibited by the antagonist of the genomic
ER type α (ERα) and type β (ERβ) receptors, ICI182780
and 2-phenyl-3-(4-hydroxyphenyl)-5,7-bis(trifluoromethyl)-
pyrazolo[1,5-a]pyrimidine (PHTPP), respectively, highlighting
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a classical genomic mechanism. Nevertheless, the specific block
of the intracellular signaling cascade of the extracellular
signal-regulated protein kinase 1/2 (ERK1/2) or AKT
(commonly downstream the activation of the membrane
receptor) evidenced that also these pathways may occur,
and suggested that the mechanisms are complicated, likely
involving both genomic and non-genomic actions (Gu
et al., 2018). Besides, also PROG was able to promote SC
proliferation, and its effects appeared sex-specific (Jung-
Testas et al., 1993). E2 was effective in males, while PROG
promotes SC proliferation only in females. These actions implied
genomic mechanisms since they were blocked by specific ERα
and PR antagonists, ICI128780 and zk112994, respectively,
(Fex Svenningsen and Kanje, 1999).
In the PNS, the effect of neuroactive steroids been extensively
studied on the myelination and re-myelination processes has
been extensively studied. The glucocorticoid corticosterone
stimulated the expression of the two most important proteins of
the peripheral myelin (Desarnaud et al., 2000): the glycoprotein
P0 (P0) and the peripheral myelin protein of 22 kDa (PMP22).
However, progestogens were proved as the more compelling
steroids able to regulate the PNS myelination. PROG, DHP,
and ALLO stimulated the expression of P0 and PMP22 in the
sciatic nerve of young and old male rats (Melcangi et al., 1998,
1999a, 2000b; Faroni and Magnaghi, 2011). In in vivo models,
PROG, DHP and ALLO proved able to reduce the age-associated
myelin abnormalities in the sciatic nerve of elderly rats (Azcoitia
et al., 2003) and stimulated the re-myelination of injured nerves,
in a model of nerve cryolesion or transection (Koenig et al.,
1995; Melcangi et al., 2000a). Furthermore, in a model of guided
facial nerve regeneration, PROG increased the SC proliferation,
myelination as well as the number of nerve fibers (Chavez-
Delgado et al., 2005). The effects of PROG and DHP on P0 and
PMP22 levels occurred also in SC cultures (Desarnaud et al., 1998;
Melcangi et al., 1998, 1999a; Magnaghi et al., 2001), indicating
a direct classical genomic effect of progestogens on these cells.
In accordance, we proposed that the complicated and long-term
effects of PROG, DHP and ALLO (after its retro-conversion
into DHP, within PNS cells; see Figure 1) in modulating the
expression of protein P0 are linked to the interaction with the
PR expressed in SC (Magnaghi et al., 2001). The specific PR
antagonist mifepristone (RU38486), indeed, blocked the effects
of PROG, DHP and ALLO on the P0 levels (Melcangi et al.,
2003), corroborating the genomic mechanism. Nevertheless, the
rapid effect of ALLO on PMP22 levels seemed due to an
interaction with the GABA-A receptor expressed in SC (see
the chapter below).
The classical genomic effect on P0 was sustained by the
presence of putative PROG responsive elements on the P0
gene (Magnaghi et al., 1999) and by the involvement of the
steroid nuclear receptor coactivator SRC1 in the regulation of
P0 expression (Cavarretta et al., 2004). Interestingly, the genomic
action exerted by progestogens on the PNS myelin proteins, that
is P0, PMP22 and myelin associated glycoprotein (MAG), was
sex-specific; in fact male rats resulted more responsive to the
genomic effects of PROG and DHP (Magnaghi et al., 2006b).
It was highlighted that PROG coordinates also the initiation
of the PNS myelination, because it increases the expression of
some basic transcription factors priming the SC myelination,
such as early growth response 2 EGR2 (EGR2/Krox-20), early
growth response (EGR1/Krox-24), early growth response 3 (Egr-
3), SRY-box10 (Sox10) and Fos B (Guennoun et al., 2001; Mercier
et al., 2001; Magnaghi et al., 2007). At least in the case of
Krox-20, the presence of putative PROG responsive elements
in the gene promoter support a PR-mediated genomic effect
(Magnaghi et al., 2007).
Other findings suggested that the glycoprotein P0 is also under
the control of classical AR. Gonadectomy of adult male rats
induced a decrease in myelin protein P0, whereas DHT enhanced
the P0 levels in sciatic nerve of normal animals (Magnaghi et al.,
1999). This effect attested the capacity of androgens to participate
in the control of peripheral myelination, however, since the SC do
not express AR (Magnaghi et al., 1999), the effect was supposed
to be indirectly mediated via the neuronal compartment. The
androgens efficacy may be ascribed to the crosstalk between
SC and the axon, hypothesizing the transfer of vesicles likely
containing the receptors (Grossfeld et al., 1988; Lopez-Verrilli
and Court, 2012), or the involvement of motoneurons which
express the AR (Jordan et al., 2002). The finding that genomic
effects of neuroactive steroids on SC are indirectly mediated by
the neuronal compartment is supported by the observation that
the PR antagonist mifepristone induced an axonal impairment
during the development, determining a significant reduction
of axon diameter (Melcangi et al., 2003). In accordance, the
PROG enhancement of myelin formation was shown in an
in vitro co-culture model of SC-DRG neurons, corroborating the
requirement of the neuronal compartment for the progestogen
action (Chan et al., 2000).
Neuroactive steroids, mainly PROG and DHP, also exert
neuroprotective and pro-regenerative effects in case of
neurodegenerative pathologies of the PNS, such as nerve
traumatic injuries (i.e., cryolesion, transection or crush) or
diabetic neuropathy (Koenig et al., 1995; Melcangi et al., 2000a;
Chavez-Delgado et al., 2005; Leonelli et al., 2007; Roglio et al.,
2008). For instance, PROG and DHP, likely through genomic
mechanisms involving the PR, are able to counteract the decrease
of P0 and PMP22 expression induced in the STZ model of
diabetic neuropathy (Leonelli et al., 2007). Both neuroactive
steroids decreased the number of altered fibers (i.e., presenting
myelin infoldings) in the sciatic nerve of STZ neuropathic rats
(Veiga et al., 2006), still corroborating the neuroprotective role
of PR. In parallel, also the androgen DHT proved able to increase
the P0 mRNA levels in the sciatic nerve of STZ neuropathic
rats, likely via AR-mediated mechanisms (Roglio et al., 2007).
In the same model of STZ-induced neuropathy, DHP and DHT
improved another hallmark of diabetic neuropathy, promoting
the changes in Na+-K+ ATPase activity (Leonelli et al., 2007;
Roglio et al., 2007). In diabetic rats, also the treatment with
DHEA exerted neuroprotective effects, mostly in females rather
than in male animals (Pesaresi et al., 2011b). DHEA was effective
following rat sciatic nerve transection, whereas it reduced the
extent of denervation atrophy stimulating the earlier onset of
axonal regeneration (Ayhan et al., 2003). Following traumatic
nerve crush injury, DHEA and E2 promote the fast recovery of
Frontiers in Neuroscience | www.frontiersin.org 4 July 2020 | Volume 14 | Article 796
fnins-14-00796 July 27, 2020 Time: 18:11 # 5
Colciago et al. Neurosteroid Functions in Peripheral Nervous System
gait along with an enhancement of myelinated fibers (Gudemez
et al., 2002; Islamov et al., 2002). Moreover, also T was capable
to accelerate the functional recovery following rat sciatic nerve
crush (Kujawa et al., 1993; Brown et al., 1999).
Evidence of GR-dependent induction of gene transcription
was found in adult DRG neurite, which grew in response to stress
or glucocorticoid treatment. This phenomenon exacerbates the
effect of acute systemic stress on neuronal plasticity and PNS
regeneration (Lerch et al., 2017). Importantly, a putative role of
GR in regulating peripheral nociception has been proposed. This
hypothesis was corroborated by the GR localization, which was
found predominantly in peripheral nociceptive unmyelinated
C-fiber and Aδ lightly myelinated fibers (Shaqura et al., 2016).
NON-GENOMIC ACTION OF
NEUROACTIVE STEROIDS IN PNS: ROLE
OF MEMBRANE STEROID RECEPTORS
The steroid membrane receptors mediate the rapid (second
to minutes) non-classical, non-genomic action of neuroactive
steroids, occurring at the cell surface of neurons and glial cells.
To date, it consists of specific receptors for estrogens (membrane
ER, mER), androgens (membrane AR, mAR) glucocorticoids
(membrane GR, mGR) and progestogens (membrane PR, mPR).
These receptors mostly belong to the G protein-coupled receptor
(GPCR) family and activate a plethora of intracellular signaling
cascade (Levin, 2011). Recent studies investigated the presence of
some membrane receptors in the PNS, focusing primarily on the
subfamilies mER and mPR.
The GPR30, named GPCR ER-1 (GPER1), is a non-nuclear ER
located on the cell membrane, which binds E2 with high affinity
and potency, thus mediating non-genomic events (Thomas et al.,
2005). DRG, autonomic pelvic ganglia and sensory trigeminal
ganglia express GPR30, which modulation by the specific G1
agonist induced a membrane depolarization (Dun et al., 2009).
In the PNS, however, some rapid estrogenic effect seemed to be
due to the non-genomic action of classic ERα, likely translocated
to the cell membrane. For instance, mouse DRG neurons express
membrane associated ERα, producing a rapid attenuation of
ATP-induced Ca++ signaling, likely a mechanism involved in
gender-specific pain perception (Chaban and Micevych, 2005).
Another study underlined the cytoprotective potential of E2 on
the transplanted SC in a model of spinal cord injury (Siriphorn
et al., 2010). Protection was not inhibited by classical ER
antagonist ICI 182780, suggesting that non-genomic mechanisms
involving mER may occur (Siriphorn et al., 2010).
In the last decade, five subtypes of mPRs (mPRα−ε)
were classified. These receptors are GPCRs, belong to the
progestin and adipoQ receptor family (PAQR) and mediate
rapid neuroprotective actions of progestogens (i.e., PROG and
ALLO) in the nervous system (Thomas and Pang, 2012).
The PR membrane component-1 (PGRMC-1; formerly named
25Dx) is another protein complexing with the plasminogen
activator inhibitor 1 RNA binding protein and able to bind
PROG (Peluso et al., 2008; Cooke et al., 2013). PGRMC1 was
implicated in the neuroprotective effects of PROG following
traumatic brain injury (Meffre et al., 2013) and spinal cord
injury (De Nicola et al., 2009). Although it was found in
S42 SC line (Castelnovo et al., 2019), the possible function in
PNS was not further investigated. Very recently, some mPRs
(primarily mPRα and mPRβ) were found in PNS and in SC
in vitro (Figure 2), whereby they promote cell migration,
proliferation and differentiation (Castelnovo et al., 2019, 2020).
Indeed, in SC, mPR activation with the specific ligand O2
induced rapid downregulation of myelinating (i.e., Sox10 and
Krox20) and non-myelinating [i.e., glial fibrillary acidic protein
(GFAP) and neurotrophin receptor p75 (p75-NTR)] markers
of SC. Contemporarily, other specific markers of repairing SC
[i.e., oligodendrocyte transcription factor 1 (Olig1) and sonic
hedgehog (Shh)] resulted up- and/or down-regulated following
mPR activation (Castelnovo et al., 2020). These effects were
mediated by an intracellular activation of phosphorylated AKT
(Figure 2). Overall, these observations proved a direct control of
SC by mPR, playing a promising role in the promotion of nerve
re-growth (Castelnovo et al., 2019, 2020).
Recent work shed light on a peripheral glial population
named “motor exit point” (MEP) glia, possessing some typical
features of peripheral SC, that might be relevant in spinal cord
regeneration (Fontenas and Kucenas, 2018). Theoretically, it
could be speculated that mPR exerts a direct neuroprotective
effect within the spinal cord through the mPR stimulation of MEP
glial cells, although this hypothesis deserves further proof.
Apparently less investigated, also the mGR subfamily was
studied in the PNS. Evidence of a putative non-genomic pathway
including GR binding sites has been found in membrane fractions
of DRG neurons, suggesting a potential rapid, GPCR-linked,
non-genomic mechanism for mGR in mediating peripheral pain
(Shaqura et al., 2016).
NON-GENOMIC ACTION OF
NEUROACTIVE STEROIDS IN PNS:
INVOLVEMENT OF GABA AND OTHER
RECEPTORS
Besides the steroid membrane receptors, the non-classical
action of neuroactive steroids comprises the modulation of
other membrane receptors, for instance, the neurotransmitter
receptors GABA-A, GABA type B (GABA-B), NMDA, 5-
hydroxytryptamine type 3 (5-HT3) and σ1 receptors (Lambert
et al., 1996, 2009; Rupprecht et al., 2001; Monnet and Maurice,
2006; Sedlacek et al., 2008).
GABA-A receptor is a member of the ligand-gated ion channel
family, permeable to a Cl− flux and composed of five subunits
from a repertoire of nineteen isoforms (i.e., α1-6, β1-3, γ1-3,
δ, ε, pi, θ, ρ1-3) (Whiting et al., 1995, 1997; Lambert et al.,
2003). GABA-A receptor is allosterically activated by neuroactive
steroids, mainly ALLO but also 3α-diol, 3β-diol and the
corticosteroid 5α-3α metabolite tetrahydrodesoxycorticosterone
(THDOC) (Reddy and Rogawski, 2002). In this regard, it is the
most studied non-genomic mechanism of neuroactive steroids
in the nervous system as well as in the PNS (Park-Chung et al.,
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FIGURE 2 | Scheme of main non-classical mechanisms of progestogens
(PROG, progesterone and THP, tetrahydroprogesterone also called ALLO,
allopregnanolone) in the PNS. ALLO may interact with GABA type A receptor
(GABA-A), although its modulation of GABA type B receptor (GABA-B)
receptor has been proposed. In SC, ALLO and likely PROG interact with the
membrane PROG receptor (mPR). Some intracellular signalings downstream
these receptors (including Src/FAK kinases; protein kinase C, PKC, and
PKC; cyclic AMP, cAMP, and protein kinase A, PKA, etc.) are reported (see
text for details).
1999; Belelli and Lambert, 2005). GABA-A receptor is classified in
different subtypes based on its subunit composition. The receptor
formed by one α (α2-5) plus β3 and γ2 subunits gives consistent
potentiation to the ALLO-mediated GABA-activated currents
(Hosie et al., 2009), while δ-containing subtype was classically
described at extrasynaptic sites whereby it is highly sensitive to
the 5α-3α-reduced metabolites (Mihalek et al., 1999; Belelli et al.,
2002). In the PNS, GABA-A receptor is widely distributed in
nerves, neurons, and glial cells. SC express the α2 and 3, β1,
2, 3 and γ2 subunits (Melcangi et al., 1999a; Magnaghi et al.,
2006a), as well as the α4 and δ subunits, more characteristic of the
extrasynaptic receptor (Faroni et al., 2019). In addition, we found
most of these subunits in the mouse DRG neuronal cultures, with
predominant expression of the synaptic subunits α1, α2, β1, β3,
γ2 (Faroni et al., 2019). In general, in the PNS, the role of ALLO
through GABA-A receptor has been widely characterized in the
glial compartment, showing enhancement of SC proliferation,
motility, differentiation and myelination (Figure 2; see also the
following chapter). ALLO non-classical non-genomic effects were
mimicked also by PROG and DHP, but only in prolonged (e.g.,
24 h) treatment condition, when progestogens can be converted
into their 5α-3α metabolite ALLO, then exerting its action via
GABA-A receptor modulation (Figure 2). Recently, in DRG
sensory neuron, GABA-A receptor has been characterized for its
relevance in controlling peripheral pain (Chen et al., 2014; Zhang
et al., 2015; Du et al., 2017), albeit ALLO’s allosteric modulation
of GABA-A receptor in pain was not yet fully investigated.
Interestingly, some evidence suggests that neuroactive steroids
require a different route of access to the transmembrane-domain
binding sites within GABA-A receptor (Shu et al., 2004; Akk
et al., 2005; Hosie et al., 2006; Chisari et al., 2009). Neuroactive
steroids may be entrapped in the intracellular compartment,
then re-supply the cell membrane with ligands able to modulate
the GABA-A receptor at later times; by this way, the kinetic
of neuroactive steroid action at GABA-A receptor may be
modulated by neuroactive steroids themselves (Akk et al.,
2005). In accordance, the regulation of the lipid components
of the peripheral myelin may be considered as a kind of non-
classical non-genomic action of neuroactive steroids in the PNS.
Although this uncommon mechanism was exerted by DHP,
usually acting through the classic genomic PR action, it lies
in the middle ground of a genomic/non-genomic mechanism.
However, in a model of diabetic neuropathy, DHP proved able to
promote fatty acid desaturation and to reduce the morphological
alteration of nerves, reaffirming its neuroprotective role in PNS
(Mitro et al., 2014).
In principle, the possibility of ALLO to interact with the
metabotropic GABA-B receptor should not be completely
excluded (Figure 2). To date, although a direct interaction of
ALLO with GABA-B receptor was not clearly stated, several
pieces of evidence highlighted a cross-regulation between GABA-
A and GABA-B receptors in PNS (Magnaghi, 2007; Faroni et al.,
2019). For instance, ALLO exerted a GABA-A mediated biphasic
control of different GABA-B receptor subunits (Magnaghi et al.,
2006a; Magnaghi, 2007). The metabotropic GABA-B receptor is
a dimeric complex, a member of the GPCR superfamily (Bowery
and Enna, 2000). In the PNS, GABA-B receptor subunits 1a, 1b
and 2 were found in SC, sciatic nerve, satellite cells and DRG
neurons (Magnaghi et al., 2004; Magnaghi, 2007; Faroni et al.,
2014), where the functional receptor was proved to be negatively
coupled to the adenylate cyclase system (Figure 2; Magnaghi
et al., 2004). Its activation decreased SC proliferation and the
expression of some important myelin proteins, like P0, PMP22,
MAG and connexin 32 (Magnaghi et al., 2004). In a neuropathic
model of partial sciatic ligation, a 7-day administration of
specific GABA-B ligands (i.e., baclofen and the antagonist
CGP56433) strongly improved the biochemical, morphological
and behavioral outcomes of sciatic nerve (Magnaghi et al.,
2014). Furthermore, studies in transgenic mice with a conditional
deletion of GABA-B1 receptor in PNS demonstrated that some
important GABA-A subunits, expressed in SC and DRG neurons,
were cross-regulated by GABA-B receptor (Faroni et al., 2019).
Beside the GABA-A receptor, other neurotransmitter
receptors, such as NMDA receptor, are affected by neuroactive
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steroids (Figure 1). Indeed, it was shown that PREG, DHEA and
DHEA sulfate activate allosterically NMDA receptor (Figure 1),
while PREG sulfate acts as the negative modulator (Wu et al.,
1991; Baulieu, 1997; Park-Chung et al., 1999). NMDA is an
ionotropic glutamate receptor also distributed in the PNS, where
it localizes in peripheral axons and SC (Evans et al., 1991, 1992;
Carlton et al., 1998; Christensen et al., 2016; Campana et al.,
2017). The PNS also has specific glutamate transporters and it
synthesizes glutamate, which was found in sensory and motor
neurons (Chen et al., 2017). Moreover, sensory cranial ganglia
synthesize glutamate (Malet and Brumovsky, 2015), while the SC
possess the enzymatic machinery able to uptake and synthesize
glutamate, like the excitatory amino acid transporter 1 (EAAC1)
and glutamine synthetase (Miller et al., 2002; Perego et al.,
2012). The σ1 receptor is an intracellular protein that localizes
in membranes of the endoplasmic reticulum, plasmalemma,
nucleus, and mitochondria (Alonso et al., 2000) and it is able to
enhance NMDA activity (Pabba and Sibille, 2015). Activation of
this receptor rises intracellular Ca++ influx via NMDA (Hayashi
et al., 2000), thus confirming the capability of σ1 to modulate
NMDA receptor. Accordingly, it was shown that DHEA sulfate
acts as σ1 agonist, inducing a clear σ1-like potentiation of NMDA
response, while PREG sulfate exerted opposite effects; also PROG
is an endogenous antagonist of σ1 receptor (Maurice et al., 1999).
To date, evidence of neuroactive steroid actions through NMDA
or σ1 receptor, specifically in the PNS, has not been yet provided.
ALLO ACTIVATION OF GABA-A
RECEPTOR IN PNS: INTRACELLULAR
SIGNALING
ALLO is the most re-known neuroactive steroid able to regulate
the PNS, controlling glial proliferation, differentiation and
myelination processes (Figure 2). ALLO non-genomic effects on
GABA-A receptors usually occurred at nanomolar concentration,
engaging an allosteric interaction that entails the presence of
the endogenous ligand GABA. Instead, at high concentration
(micromolar range) ALLO directly gates GABA-A receptor
(Callachan et al., 1987), although it was shown that neuroactive
steroids might directly gate GABA-A receptor even at 100 nM,
likely attaining a relatively low kinetic (Shu et al., 2004).
In any case, the presence of endogenous GABA is a
requisite for ALLO action. Following the former observation
in the early 1980’s proving GABAergic fibers in PNS (Brown
and Marsh, 1978; Morris et al., 1983; Olsen et al., 1984),
it was unequivocally demonstrated the presence of GABA
and its synthetic machinery (glutamic acid decarboxylase
of 67 kDa, GAD67) in SC (Magnaghi et al., 2010). An
autocrine loop has been proposed, through which nanomolar
concentration of ALLO was able to increase the GAD67
levels in SC, thus providing GABA as the endogenous
ligand for the GABA-A receptor (Magnaghi et al., 2010).
Therefore, the local GABA synthesis in peripheral nerves
supports the allosteric action of ALLO in SC and neighboring
compartments. In accordance, it was shown that SC possesses
EAAC1, the active uptake system able to provide glutamate
as a precursor for GABA synthesis (Perego et al., 2011,
2012). In SC, EAAC1 expression and activity were still
controlled by ALLO, through a GABA-A mediated and protein
kinase C (PKC) mechanisms (Figure 2) ALLO promoted the
transport of EAAC1 from the intracellular stores into the SC
membrane (in actin-rich cell tips), modifying their morphology
(Perego et al., 2012).
ALLO was shown to increase SC proliferation (Perego
et al., 2012; Melfi et al., 2017) and this action was GABA-
A mediated because it was mimicked by the specific ligand
muscimol and blocked by the specific antagonist bicuculline
(Perego et al., 2012). It was highlighted that ALLO’s control
of SC proliferation was dependent on EAAC1 transport and
activity at SC plasma membrane (Perego et al., 2012), once
again confirming that GABA synthesis was necessary for ALLO
effects. ALLO also stimulated morphologic changes and motility
of SC, then promoting myelination (Melfi et al., 2017), which
are fundamental processes for the development, maturation, and
regeneration of PNS. Remarkably, ALLO participated in the
control of peripheral myelin proteins (e.g., P0, MAG), being
particularly active in enhancing the levels of PMP22, mRNA
and protein (Melcangi et al., 1999a,b; Magnaghi et al., 2001).
The specificity of this action was confirmed, respectively, by
the capability of muscimol to replicate and of bicuculline to
abolish the ALLO’s effects on PMP22 (Magnaghi et al., 2001,
2006a). This confirmed the hypothesis that in SC protein PMP22
is controlled by GABA-A receptors. However, the capability to
stimulate PMP22 expression was observed also with 3α-diol
(Magnaghi et al., 2001), likely via the same allosteric GABA-A
receptor modulation (Frye et al., 1996; Figure 1).
As expected, the intracellular mechanisms downstream the
ALLO modulation of GABA-A receptors imply changes in
intracellular Cl− flux (Figure 2). Conversely, at least in PNS,
most of ALLO effects reflected as transcriptional changes. In
the last decades, some studies were addressed to clear this
point. For instance, in the developing rat cortex, GABA-
A receptor activation leads to an increase of Ca++ influx
through L-type voltage-gated Ca++ channels. This leads to the
phosphorylation and activation of the cAMP response element-
binding protein (CREB) transcription factor, in turn regulating
protein expression, for instance of the brain derived neurotrophic
factor (Mantelas et al., 2003). Unfortunately, these mechanisms
were not shown in the PNS, whereas the concomitant activation
of ion channels (e.g., Ca++ channels), following neuroactive
steroid binding to GABA-A receptor, is still questionable.
Although the involvement of Ca++ channel is not clear, ALLO
was proved able to modulate the protein kinase A (PK-A),
through enhanced cAMP levels and CREB phosphorylation
(Magnaghi et al., 2010), or the PKC pathway (Perego et al., 2012;
Figure 2). These intracellular signalings were supposed to be
downstream the allosteric action of ALLO at GABA-A receptor.
Recently, another intracellular ALLO’s pathway has been found.
ALLO effects on SC proliferation, motility and myelination,
indeed, imply tyrosine protein kinase Src (Src) and focal adhesion
kinase (FAK) activation (Melfi et al., 2017), although other
signaling pathways should not be excluded (Figure 2). ALLO
effects on Src were mimicked by muscimol, counteracted by
bicuculline and by the specific Src inhibitor PP2, suggesting
that in SC ALLO activation of GABA-A induces an intracellular
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phosphorylation cascade, leading to actin rearrangements of the
cytoskeleton, enhancement of SC motility and myelination (Melfi
et al., 2017; Figure 2).
One strategy that neuroactive steroids use to control GABA-
A receptor function is to phosphorylate/de-phosphorylate its
subunits by the recruitment of protein kinases or phosphatases
(Belelli and Lambert, 2005). Phosphorylation of GABA-A
can produce different effects, ranging from enhancement to
inhibition, depending on the subunit targeted and on the
location of sites being phosphorylated (Moss and Smart, 1996).
In parallel, PKC phosphorylation of GABA-A receptor may
influence the sensitivity to neuroactive steroids (Brussaard and
Koksma, 2003; Vergnano et al., 2007). Accordingly, PKC-ε is
considered as a novel isoform of PKC, regulating the sensitivity
to neuroactive steroids. Indeed, animals lacking PKC-ε showed
hypersensitivity to behavioral effects induced with allosteric
GABA-A receptor modulation (Hodge et al., 2002). PKC-ε was
found in SC and DRG neurons in culture (Puia et al., 2015).
Interestingly, PKC-ε was upregulated in DRG neurons exposed
to the culture medium from ALLO-treated SC, suggesting
that these cells release one or more factors able to regulate
PKC-ε in DRG neurons (Puia et al., 2015). Since PKC-ε is
relevant in modulating some pain pathways, we speculated that
these mechanisms identified novel putative circuits involved in
the control of pain processes at PNS and spinal cord levels
(Puia et al., 2015).
In the PNS, ALLO hired importance also during
neurodegenerative conditions, likely implying the regulation
of other nervous cells or structures (i.e., DRG neurons). In a
model of STZ-induced diabetic neuropathy, ALLO and 3α-diol
enhanced nerve conduction velocity (NCV) and intraepidermal
nerve density, decreasing sensitivity to thermal pain (Leonelli
et al., 2007; Roglio et al., 2007). Although the mechanism
behind these effects was not elucidated, the involvement of
non-genomic mechanisms through GABA-A receptor was
hypothesized. In support of the non-genomic action of ALLO
in neuropathic pain (Patte-Mensah et al., 2014), it should be
highlighted that ALLO may regulate other channels and/or
signaling pathways involved in neuropathic pain, such as
T-type Ca++ channels, voltage-gated Na+ channels, purinergic
receptor P2X3 and bradykinin signaling (Cho and Chaban, 2012;
Ayoola et al., 2014).
CONCLUSION
In this review, we sum up most of the latest evidence on the
effects of neuroactive steroids, either classical or non-classical,
genomic or non-genomic, in the PNS. Neuroactive steroids
exhibit important functions in the development, myelination,
neuroprotection and nerve repair of the PNS. In particular,
ALLO revealed the most well studied and incisive neuroactive
steroid in regulating the biologic and physiologic functions
of the PNS. Here we reported several steps forward in the
identification of its mechanism of action. Some ALLO’s effects
may be ascribed to GABA-A (or likely GABA-B) activation, PKA,
PKC or PKC-ε modulation, as well as to the Src/FAK kinases
involvement. Besides, mPR or electrophysiological changes in ion
channels, likely Cl− flux, have been recently proposed to occur
also in the PNS.
Interestingly, the neuroregenerative effects of ALLO via
GABA-A receptor might be promising for the treatment
of the peripheral neurodegenerative pathologies, particularly
for traumatic injuries requiring the surgical application of
bioengineered conduits. Indeed, in vitro testing of 2D silk fibroin
scaffold, functionalized for controllable in situ delivery of ALLO,
showed great potential for nerve repair (Gennari et al., 2018).
Therefore, the administration of neuroactive steroids might
represent a novel and promising strategy to prevent or treat
different types of peripheral neuropathies and the associated
neuropathic pain.
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